X4 Pharmaceuticals
XFOR
29 hedge funds and large institutions have $31.1M invested in X4 Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 9 closing their positions.
21% more capital invested
Capital invested by funds: $25.7M → $31.1M (+$5.45M)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.46% more ownership
Funds ownership: 0.43% → 0.89% (+0.46%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
19% less funds holding
Funds holding: 36 → 29 (-7)
78% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$611K |
| 2 |
TCIM
TIAA CREF Investment Management
New York
|
+$113K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$54.6K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$34.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$29.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$1.06M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$127K |
| 3 |
VF
Virtu Financial
New York
|
-$82K |
| 4 |
Squarepoint
New York
|
-$81K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$64K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $3K | -$18.2K | -33 | -85% |
|
|
SO
27
STRS Ohio
Columbus,
Ohio
| $3K | – | – | – |
|
28
Legal & General Group
London,
United Kingdom
| $2K | – | – | – |
|
|
AIP
29
Ameritas Investment Partners
Lincoln,
Nebraska
| $1K | – | – | – |
|
|
30
Northern Trust
Chicago,
Illinois
| – | -$127K | -303 | Closed |
|
|
VF
31
Virtu Financial
New York
| – | -$82K | -196 | Closed |
|
|
32
Squarepoint
New York
| – | -$81K | -193 | Closed |
|
|
OAM
33
Oxford Asset Management
Oxford,
United Kingdom
| – | -$64K | -153 | Closed |
|
34
Bank of New York Mellon
New York
| – | -$59K | -141 | Closed |
|
|
PPA
35
Parametric Portfolio Associates
Seattle,
Washington
| – | -$59K | -140 | Closed |
|
36
Goldman Sachs
New York
| – | -$54K | -130 | Closed |
|
37
Two Sigma Investments
New York
| – | -$50K | -119 | Closed |
|
|
CA
38
Claro Advisors
Boston,
Massachusetts
| – | -$1K | -2 | Closed |
|
39
BNP Paribas Financial Markets
Paris,
France
| – | -$158 | – | – |
|
XFOR Hedge Fund Activity: Q1 2019 in Review
29 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q1 2019, worth a combined $31.1M — up 21% from $25.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of XFOR and 2 opened new positions — a net loss of 7 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $611K. The largest seller was Cormorant Asset Management, cutting an estimated $1.06M.
- 29 institutional investors held X4 Pharmaceuticals (XFOR) as of Q1 2019, down from 36 in Q4 2018.
- Funds reported $31.1M of X4 Pharmaceuticals stock for Q1 2019, up 21% quarter-over-quarter.
- 2 funds opened new X4 Pharmaceuticals positions in Q1 2019 and 9 closed out, a net change of -7 holders.
- The largest X4 Pharmaceuticals buyer in Q1 2019 was Vanguard Group, an estimated $611K added.
- The largest X4 Pharmaceuticals seller in Q1 2019 was Cormorant Asset Management, an estimated $1.06M sold.
Based on aggregated 13F filings for Q1 2019.